Sponsor Pipeline

Replimune Inc. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
6
Active Trials
3
Recruiting
1
Phase 3
5
Disease Areas
Active Trials by Phase
Phase 2/3
1
Phase 2
2
Phase 1
2
Not specified
1
Active Trials
NCT IDTitleConditionStatus
Phase 2/3
NCT06581406 A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in… Metastatic Uveal Melanoma Recruiting
Phase 2
NCT05733598 Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or… Hepatocellular Carcinoma Recruiting
NCT03767348 Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) Non-Small Cell Lung Cancer (NSCLC) Active, Not Recruiting
Phase 1
NCT04336241 Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid… Cancer Active, Not Recruiting
NCT04735978 Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid… Advanced Solid Tumor Active, Not Recruiting
Not specified
NCT06887348 A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1… Melanoma Recruiting
Disease Areas
Get alerts when Replimune Inc.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free